Digest Network How does it work
Network
/
Society
AN
Not verified

AN2 Therapeutics, Inc.

What we write about

BiotechnologyHealthHIV, AIDS and autoimmune disordersPharmaceuticalsScienza

24 Press releases

View all press releases
12/11/2025
Scienza
Biotechnology
Pharmaceuticals
Oncology
Sanità
Health
HIV, AIDS and autoimmune disorders
stock market
AN2 Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business and Scientific Highlights
Source
AN2 Therapeutics, Inc.
Issuer
Business Wire
1.00
0
10/11/2025
Scienza
Biotechnology
Pharmaceuticals
Oncology
Health
HIV, AIDS and autoimmune disorders
Medicine - various
Labour market
Industria
AN2 Therapeutics Announces Research Collaboration With GSK to Advance Boron-Based LeuRS-Inhibitors Targeting Tuberculosis (TB)
Source
AN2 Therapeutics, Inc.
Issuer
Business Wire
1.00
0
06/11/2025
Eventi
WEB AND SOCIAL NETWORK
Health
HIV, AIDS and autoimmune disorders
Scienza
Pharmaceuticals
Biotechnology
AN2 Therapeutics to Participate in Fireside Chat at Evercore HealthCONx Conference
Source
AN2 Therapeutics, Inc.
Issuer
Business Wire
1.00
0
12/08/2025
Biotechnology
HIV, AIDS and autoimmune disorders
Health
Pharmaceuticals
Oncology
WEB AND SOCIAL NETWORK
Phones and Miscellaneous
stock market
AN2 Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business and Scientific Highlights
Source
AN2 Therapeutics, Inc.
Issuer
Business Wire
1.00
0
12/08/2025
Health
HIV, AIDS and autoimmune disorders
Medicine - various
Scienza
Pharmaceuticals
Biotechnology
Industria
AN2 Therapeutics Commences First-in-Human Clinical Trial of Oral AN2-502998 for Chagas Disease
Source
AN2 Therapeutics, Inc.
Issuer
Business Wire
1.00
0
23/07/2025
Health
HIV, AIDS and autoimmune disorders
Scienza
Pharmaceuticals
Biotechnology
Labour market
AN2 Therapeutics and DNDi Collaborate on Clinical Development of Promising New Oral Compound to Treat Chronic Chagas Disease
Source
AN2 Therapeutics, Inc.
Issuer
Business Wire
1.00
0
30/06/2025
Scienza
HIV, AIDS and autoimmune disorders
Food hygiene
Sanità
Medicine - various
Biotechnology
Health
Pharmaceuticals
Industria
AN2 Therapeutics Reports Key Insights from 200-Patient Observational Study in Acute Melioidosis, Laying Groundwork for Phase 2 Proof-of-Concept Trial of Epetraborole
Source
AN2 Therapeutics, Inc.
Issuer
Business Wire
1.00
0
29/05/2025
Biotechnology
Pharmaceuticals
Health
Eventi
AN2 Therapeutics Announces Poster Presentation Highlighting M. Abscessus Data at 2025 Colorado Mycobacteria Conference
Source
AN2 Therapeutics, Inc.
Issuer
Business Wire
1.00
0
13/05/2025
stock market
Biotechnology
HIV, AIDS and autoimmune disorders
Health
Pharmaceuticals
Medicine - various
AN2 Therapeutics Reports First Quarter 2025 Financial Results and Recent Business and Scientific Highlights
Source
AN2 Therapeutics, Inc.
Issuer
Business Wire
1.00
0
01/05/2025
Scienza
Biotechnology
Pharmaceuticals
Oncology
Health
HIV, AIDS and autoimmune disorders
Medicine - various
AN2 Therapeutics Reports Data from the Phase 3 Portion of Previously Terminated EBO-301 Study and Outlines Future Milestones from Boron Chemistry Pipeline
Source
AN2 Therapeutics, Inc.
Issuer
Business Wire
1.00
0

Contact details

Social Media

Followers
0
Compatibility
0